ESC 365 - EPA based therapy in CAD: What do we know?

Open Access

EPA based therapy in CAD: What do we know?

Session: Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Speaker: Professor L. Tokgozoglu (Ankara, TR)

Sponsored by PACE-CME

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Lale Tokgozoglu

Hacettepe University, Ankara (Türkiye)

37 presentations

5 followers

2 more presentations in this session

Unravelling the triglycerides story: Lessons from genetics and clinical trials.

Speaker: Professor P. Libby (Boston, US)

Integrating EPA based therapy in the management of residual risk.

Speaker: Professor P. Steg (Paris, FR)

Access the full session

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Speakers: Professor L. Tokgozoglu, Professor P. Libby, Professor P. Steg

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by